TY  - JOUR
AU  - Livingstone, E.
AU  - Gogas, H.
AU  - Kandolf-Sekulovic, L.
AU  - Meier, F.
AU  - Eigentler, T. K.
AU  - Ziemer, M.
AU  - Terheyden, P. A. M.
AU  - Gesierich, A. H.
AU  - Herbst, R. A.
AU  - Kähler, K. C.
AU  - Ziogas, D. C.
AU  - Mijuskovic, Z.
AU  - Garzarolli, M.
AU  - Garbe, C.
AU  - Roesch, A.
AU  - Ugurel, S.
AU  - Gutzmer, R.
AU  - Grob, J. J.
AU  - Kiecker, F.
AU  - Utikal, J.
AU  - Windemuth-Kieselbach, C.
AU  - Eckhardt, S.
AU  - Zimmer, L.
AU  - Schadendorf, D.
TI  - Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
JO  - European journal of cancer
VL  - 190
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-01425
SP  - 112941
PY  - 2023
AB  - ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma.In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1). Primary outcome was PFS1 (time from start of run-in until PD1 or death). OS and safety were also assessed.Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n = 69; Arm B, n = 66). Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9months; hazard ratio [HR] 0.55; 95
KW  - Checkpoint inhibition (Other)
KW  - First-line (Other)
KW  - Melanoma (Other)
KW  - Run-in (Other)
KW  - Sequence (Other)
KW  - Targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37482012
DO  - DOI:10.1016/j.ejca.2023.112941
UR  - https://inrepo02.dkfz.de/record/277708
ER  -